A Multicenter, Randomized, Assessor-Blind Study to Evaluate Efficacy and Safety of Daptomycin Versus Vancomycin or Teicoplanin for Treatment of Complicated Skin and Soft Tissue Infections (cSSTI)

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 12 Apr 2022

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Daptomycin (Primary) ; Daptomycin; Teicoplanin; Teicoplanin; Vancomycin; Vancomycin
Indications Bacterial infections; Skin and soft tissue infections
Focus Therapeutic Use
Sponsors Novartis

08 Apr 2022 This trial has been completed in Spain (End Date: 06 May 2008), according to European Clinical Trials Database record.
10 Jul 2012 Trial phase changed from IV to III, actual patient number changed from 280 to 194 and additional trial locations added as reported by ClinicalTrials.gov.
10 Jul 2012 Status changed from completed to discontinued as reported by ClinicalTrials.gov.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com